Debanjana Chatterjee
Stock Analyst at Jones Trading
(0.64)
# 3,780
Out of 4,829 analysts
8
Total ratings
42.86%
Success rate
-16.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $26.25 | +48.57% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $11.90 | +152.21% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $3.87 | +494.32% | 1 | Mar 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $42 | $3.26 | +1,188.34% | 1 | Jan 27, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Hold | n/a | $14.10 | - | 1 | Dec 11, 2024 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $16.60 | +177.11% | 1 | Sep 19, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Buy | $41 | $8.12 | +404.93% | 1 | Sep 17, 2024 |
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $26.25
Upside: +48.57%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $11.90
Upside: +152.21%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $3.87
Upside: +494.32%
Sagimet Biosciences
Jan 27, 2025
Initiates: Buy
Price Target: $42
Current: $3.26
Upside: +1,188.34%
Spyre Therapeutics
Dec 11, 2024
Initiates: Hold
Price Target: n/a
Current: $14.10
Upside: -
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $16.60
Upside: +177.11%
Intellia Therapeutics
Sep 17, 2024
Initiates: Buy
Price Target: $41
Current: $8.12
Upside: +404.93%